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Résumé en
anglais
Obesity and type 2 diabetes mellitus (T2DM) progress worldwide with detrimental
effects on several physiological systems including bone tissue mainly by affecting bone
quality. Several gut hormones analogues have been proven potent in ameliorating bone
quality. In the present study, we used the leptin receptor-deficient db/db mice as a
model of obesity and severe T2DM to assess the extent of bone quality alterations at
the organ and tissue levels. We also examined the beneficial effects of gut hormone
therapy in this model by using a new triple agonist ([d-Ala(2)]GIP-Oxm) active at the
GIP, GLP-1 and glucagon receptors. As expected, db/db mice presented with dramatic
alterations of bone strength at the organ level associated with deterioration of
trabecular and cortical microarchitectures and an augmentation in osteoclast numbers.
At the tissue level, these animals presented also with alterations of bone strength
(reduced hardness, indentation modulus and dissipated energy) with modifications of
tissue mineral distribution, collagen glycation and collagen maturity. The use of [d-
Ala(2)]GIP-Oxm considerably improved bone strength at the organ level with modest
effects on trabecular microarchitecture. At the tissue level, [d-Ala(2)]GIP-Oxm
ameliorated bone strength reductions with positive effects on collagen glycation and
collagen maturity. This study provides support for including gut hormone analogues as
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